Preclinical characterization of gsk2336805, a novel inhibitor of hepatitis c virus replication that selects for resistance in ns5a

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 38-47

  Walker, Jill ^a   Crosby, Renae ^a   Wang, Amy ^a   Woldu, Ermias ^a   Vamathevan, Jessica ^b   Voitenleitner, Christian ^a   You, Shihyun ^a   Remlinger, Katja ^a   Duan, Maoshang ^a   Kazmierski, Wieslaw ^a   Hamatake, Robert ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GSK 2336805; NONSTRUCTURAL PROTEIN 5A; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CELL DEATH; CELL GROWTH; CONSENSUS SEQUENCE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DNA VIRUS; DRUG POTENCY; GENE SEQUENCE; GENOTYPE; HEPATITIS C VIRUS; MUTATION; NONHUMAN; PHYLOGENETIC TREE; PRIORITY JOURNAL; REPLICON; RNA REPLICATION; RNA VIRUS; VIRUS REPLICATION;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; MUTATION; REPLICON; VIRUS REPLICATION;

EID: 84891533036     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01363-13     Document Type: Article

References (50)

1. Lavanchy D. 2011. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17:107-115. http://dx.doi.org/10.1111/j.1469-0691.2010 .03432.x.
2. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, Richardson P, El-Serag HB. 2011. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 140:1182-1188. http://dx.doi.org/10.1053/j.gastro.2010.12.032.
3. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362. http://dx.doi.org/10.1126/science.2523562
4. Poenisch M, Bartenschlager R. 2010. New insights into structure and replication of the hepatitis C virus and clinical implications. Semin. Liver Dis. 30:333-347. http://dx.doi.org/10.1055/s-0030-1267535.
5. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113. http://dx.doi.org/10.1126/science.285.5424.110.
6. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM. 2003. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J. Virol. 77:3181-3190. http://dx.doi.org/10.1128/JVI.77.5.3181-3190.2003.
7. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-1817. http://dx.doi.org/10.1053/j.gastro. 2003.09.023.
8. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796. http://dx.doi.org/10.1038/nm1268.
9. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626. http://dx.doi.org/10.1126/science.1114016.
10. Ikeda M, Yi M, Li K, Lemon SM. 2002. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J. Virol. 76:2997-3006. http://dx.doi.org/10.1128/JVI.76 .6.2997-3006.2002.
11. Poordad F, McCone J, Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364: 1195-1206. http://dx.doi.org/10. 1056/NEJMoa1010494.
12. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364:2405-2416. http://dx.doi.org/10.1056/NEJMoa1012912.
13. Coelmont L, Hanoulle X, Chatterji U, Berger C, Snoeck J, Bobardt M, Lim P, Vliegen I, Paeshuyse J, Vuagniaux G, Vandamme AM, Bartenschlager R, Gallay P, Lippens G, Neyts J. 2010. DEB025 (Alisporivir) inhibits hepatitisCvirus replication by preventing a cyclophilinAinduced cis-trans isomerisation in domain II of NS5A. PLoS One 5:e13687. http://dx.doi.org/10.1371/journal.pone. 0013687.
14. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer S, Landthaler M, Landgraf P, Kan S, Lindenbach BD, Chien M, Weir DB, Russo JJ, Ju J, Brownstein MJ, Sheridan R, Sander C, Zavolan M, Tuschl T, Rice CM. 2007. Cellular cofactors affecting hepatitis C virus infection and replication. Proc. Natl. Acad. Sci. U. S. A. 104:12884-12889. http://dx.doi.org/10.1073/pnas. 0704894104.
15. Berger KL, Kelly SM, Jordan TX, Tartell MA, Randall G. 2011. Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication. J. Virol. 85:8870-8883. http://dx.doi.org/10.1128/JVI.00059-11.
16. Lohmann V, Hoffmann S, Herian U, Penin F, Bartenschlager R. 2003. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J. Virol. 77:3007-3019. http://dx.doi.org/10.1128/JVI.77.5.3007 -3019.2003.
17. van den Hoff MJ, Moorman AF, Lamers WH. 1992. Electroporation in 'intracellular' buffer increases cell survival. Nucleic Acids Res. 20:2902. http://dx.doi.org/10.1093/nar/20.11.2902.
18. Voitenleitner C, Bechtel J, Arfsten A, Hamatake R. 2012. Hepatitis C genotype 1a replicon improved through introduction of fitness mutations. Biotechniques 52:273-275. http://dx.doi.org/10.2144/000113841.
19. Blackham S, Baillie A, Al-Hababi F, Remlinger K, You S, Hamatake R, McGarvey MJ. 2010. Gene expression profiling indicates the roles of host oxidative stress, apoptosis, lipid metabolism, and intracellular transport genes in the replication of hepatitis C virus. J. Virol. 84:5404-5414. http://dx.doi.org/10.1128/JVI.02529-09.
20. Edgar RC. 2004. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32:1792-1797. http://dx.doi.org/10.1093/ nar/gkh340.
21. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagace L, Laplante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St GR, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinas-Brunet M. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189. http://dx.doi.org/ 10.1038/nature02099.
22. Miller JF, Chong PY, Shotwell JB, Catalano JG, Tai VW, Fang J, Banka AL, Roberts CD, Youngman M, Zhang H, Xiong Z, Mathis A, Pouliot JJ, Hamatake RK, Price DJ, Seal JW, III, Stroup LL, Creech KL, Carballo LH, Todd D, Spaltenstein A, Furst S, Hong Z, Peat AJ. 1 April 2013. Hepatitis C replication inhibitors that target the viral NS4B protein. J. Med. Chem. http://dx.doi.org/10.1021/ jm400125h.
23. Pierra C, Benzaria S, Amador A, Moussa A, Mathieu S, Storer R, Gosselin G. 2005. Nm 283, an efficient prodrug of the potent anti-HCV agent 2=-C-methylcytidine. Nucleosides Nucleotides Nucleic Acids 24: 767-770. http://dx.doi.org/10.1081/NCN-200060112.
24. Carroll SS, Ludmerer S, Handt L, Koeplinger K, Zhang NR, Graham D, Davies ME, MacCoss M, Hazuda D, Olsen DB. 2009. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virusinfected chimpanzees. Antimicrob. Agents Chemother. 53:926-934. http://dx.doi.org/10.1128/AAC.01032- 08.
25. Giuliano C, Fiore F, Di MA, Padron VJ, Bishop A, Bonelli F, Gonzalez- Paz O, Marcucci I, Harper S, Narjes F, Pacini B, Monteagudo E, Migliaccio G, Rowley M, Laufer R. 2005. Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase. Xenobiotica 35:1035-1054. http://dx.doi.org/10.1080/00498250500356548.
26. Howe AY, Cheng H, Johann S, Mullen S, Chunduru SK, Young DC, Bard J, Chopra R, Krishnamurthy G, Mansour T, O'Connell J. 2008. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob. Agents Chemother. 52:3327-3338. http://dx.doi.org/10.1128/AAC.00238-08.
27. Shaw AN, Tedesco R, Bambal R, Chai D, Concha NO, Darcy MG, Dhanak D, Duffy KJ, Fitch DM, Gates A, Johnston VK, Keenan RM, Lin-Goerke J, Liu N, Sarisky RT, Wiggall KJ, Zimmerman MN. 2009. Substituted benzothiadizine inhibitors of hepatitis C virus polymerase. Bioorg. Med. Chem. Lett. 19:4350-4353. http://dx.doi.org/10.1016/j.bmcl.2009.05.091.
28. Prichard MN, Shipman C, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:181-205. http://dx.doi.org /10.1016/0166-3542(90)90001-N.
29. Bliss CI. 1939. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26:585-615. http://dx.doi.org/10.1111/j.1744-7348.1939.tb06990.x.
30. Buckwold VE, Wei J, Wenzel-Mathers M, Russell J. 2003. Synergistic in vitro interactions between alpha interferon and ribavirin against bovineviral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication. Antimicrob. Agents Chemother. 47:2293-2298. http://dx.doi.org/10. 1128/AAC.47.7.2293-2298.2003.
31. Powdrill MH, Tchesnokov EP, Kozak RA, Russell RS, Martin R, Svarovskaia ES, Mo H, Kouyos RD, Gotte M. 2011. Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc. Natl. Acad. Sci. U. S. A. 108:20509- 20513. http://dx.doi.org/10.1073/pnas.1105797108.
32. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96-100. http://dx.doi.org /10.1038/nature08960.
33. Fridell RA, Wang C, Sun JH, O'Boyle DR, Nower P, Valera L, Qiu D, Roberts S, Huang X, Kienzle B, Bifano M, Nettles RE, Gao M. 2011. Genotypic and phenotypic analysis of variants resistant to hepatitisCvirus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: In vitro and in vivo correlations. Hepatology 54:1924-1935. http://dx.doi.org/10.1002/hep.24594.
34. Fridell RA, Qiu D, Wang C, Valera L, Gao M. 2010. Resistance analysis of the hepatitisCvirus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 54:3641-3650. http://dx.doi.org/10.1128/AAC.00556- 10.
35. Aloia AL, Locarnini S, Beard MR. 2012. Antiviral resistance and directacting antiviral agents for HCV. Antivir. Ther. 17:1147-1162. http://dx.doi.org/10.3851/IMP2426.
36. Zein NN. 2000. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. 13:223-235. http://dx.doi.org/10.1128/CMR.13.2.223 -235.2000
37. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS. 1993. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J. Gen. Virol. 74:2391-2399. http://dx.doi.org/10.1099/0022-1317-74-11- 2391.
38. Sarrazin C, Zeuzem S. 2010. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138:447-462. http://dx.doi.org/10.1053/j.gastro.2009.11.055.
39. Tellinghuisen TL, Foss KL, Treadaway JC, Rice CM. 2008. Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J. Virol. 82:1073-1083. http://dx.doi.org/10.1128/JVI.00328- 07.
40. Tellinghuisen TL, Foss KL, Treadaway J. 2008. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog. 4:e1000032. http://dx.doi.org/10.1371/journal.ppat.1000032.
41. Hughes M, Griffin S, Harris M. 2009. Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles. J. Gen. Virol. 90:1329-1334. http://dx.doi.org/10.1099/vir.0.009332-0.
42. Blight KJ, Kolykhalov AA, Rice CM. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974. http://dx.doi.org/10.1126/ science.290.5498.1972.
43. Cordek DG, Bechtel JT, Maynard AT, Kazmierski WM, Cameron CE. 2011. Targeting the NS5A protein of HCV: An emerging option. Drugs Future 36:691-711.
44. Love RA, Brodsky O, Hickey MJ, Wells PA, Cronin CN. 2009. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J. Virol. 83:4395- 4403. http://dx.doi.org/10.1128/JVI.02352-08.
45. Tellinghuisen TL, Marcotrigiano J, Rice CM. 2005. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435:374-379. http://dx.doi.org/10.1038/nature03580.
46. Bhattacharya D, Ansari IU, Hamatake R, Walker J, Kazmierski W, Striker R. 30 August 2013. Pharmacologic disruption of hepatitis C non-structural 5A (NS5A) intra and intermolecular conformations. J. Gen. Virol. http://dx.doi.org/10.1099/vir.0.054569-0.
47. Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS. 2013. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc. Natl. Acad. Sci. U. S. A. 110:3991- 3996. http://dx.doi.org/10.1073/pnas.1203110110.
48. Wilfret D, Walker J, Adkison K, Jones L, Lou Y, Gan J, Castellino S, Moseley C, Horton J, SMde Culp A, Goljer I, Spreen W. 2013. Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, aninhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1. Antimicrob. Agents Chemother. 57:5037-5044. http://dx.doi.org/10.1128/AAC.00910-13.
49. Gardner S, Cutrell A, Elko-Simms C, Adkison K, Hamatake R, Walker J, Rodriguez-Torres M, Hong Z. 25 September 2013. A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity, and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis Cvirus genotype 1-infected treatment-naive subjects. Liver Int. http://dx.doi.org/10.1111/liv.12334.
50. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Mullhaupt B, Pockros P, Terg R, Shouval D, HBvan Weiland O, Van HR, De MS, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. 2011. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364:2417-2428. http://dx.doi.org/10.1056/NEJMoa1013086.